This week’s Hunamakia longevity research roundup looks at how anti-aging science is becoming more practical, measurable, and investable.
In this episode, we cover key signals across tissue repair, stem cell rejuvenation, mitochondrial health, metabolic resets, biological age clocks, rapamycin, senolytics, GLP-1-related aging research, and the growing flow of capital into longevity companies.
The big takeaway: longevity science is shifting from vague anti-aging promises toward an engineering mindset — identify the mechanism, measure the biological change, improve the protocol, and scale what works.
Topics covered:
• Blood stem cell rejuvenation and immune resilience
• Rapamycin and aging hearts
• Choline, NMN, NAD+, diet timing, and metabolic pathways
• Senolytics, Yamanaka factors, GlyNAC, and systemic aging
• Biological age clocks and why better measurement matters
• Why investors are backing longevity as a serious emerging industry
Subscribe to the Hunamakia newsletter for more evidence-led breakdowns on longevity science, healthy lifespan extension, anti-aging research, and the business of human healthspan:
Like, subscribe, and comment with the longevity topic you want covered next.
#Longevity #AntiAging #Healthspan #Biotech #Rapamycin #Senolytics #StemCells #BiologicalAge #NAD #LongevityScience
